These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 35466182)
21. A review of thrombotic microangiopathies in multiple myeloma. Portuguese AJ; Gleber C; Passero FC; Lipe B Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728 [TBL] [Abstract][Full Text] [Related]
22. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Williams LA; Marques MB; Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904 [TBL] [Abstract][Full Text] [Related]
23. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Raufi AG; Scott S; Darwish O; Harley K; Kahlon K; Desai S; Lu Y; Tran MH Hematol Rep; 2016 Sep; 8(3):6625. PubMed ID: 27781079 [TBL] [Abstract][Full Text] [Related]
24. Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center. Martin SD; McGinnis E; Smith TW Am J Clin Pathol; 2021 Nov; 156(6):1103-1112. PubMed ID: 34160013 [TBL] [Abstract][Full Text] [Related]
25. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management. Mazzierli T; Allegretta F; Maffini E; Allinovi M Front Pharmacol; 2022; 13():1088031. PubMed ID: 36699080 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis. Paydary K; Banwell E; Tong J; Chen Y; Cuker A Transfusion; 2020 Sep; 60(9):2047-2057. PubMed ID: 32757237 [TBL] [Abstract][Full Text] [Related]
27. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Bendapudi PK; Hurwitz S; Fry A; Marques MB; Waldo SW; Li A; Sun L; Upadhyay V; Hamdan A; Brunner AM; Gansner JM; Viswanathan S; Kaufman RM; Uhl L; Stowell CP; Dzik WH; Makar RS Lancet Haematol; 2017 Apr; 4(4):e157-e164. PubMed ID: 28259520 [TBL] [Abstract][Full Text] [Related]
28. Thrombotic microangiopathies: a general approach to diagnosis and management. Arnold DM; Patriquin CJ; Nazy I CMAJ; 2017 Jan; 189(4):E153-E159. PubMed ID: 27754896 [No Abstract] [Full Text] [Related]
29. Proteasome inhibitor associated thrombotic microangiopathy. Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661 [TBL] [Abstract][Full Text] [Related]
30. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy]. Ri M Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777 [TBL] [Abstract][Full Text] [Related]
35. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Salmenniemi U; Remes K Hematol Rep; 2012 May; 4(2):e13. PubMed ID: 22826795 [TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Moore H; Romeril K Intern Med J; 2011 Apr; 41(4):348-50. PubMed ID: 21507163 [TBL] [Abstract][Full Text] [Related]
37. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Morita R; Hashino S; Shirai S; Fujita N; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M Int J Hematol; 2008 Sep; 88(2):248-250. PubMed ID: 18636313 [No Abstract] [Full Text] [Related]
38. Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Field-Smith A; Morgan GJ; Davies FE Ther Clin Risk Manag; 2006 Sep; 2(3):271-9. PubMed ID: 18360602 [TBL] [Abstract][Full Text] [Related]